Jieun Kim

Jieun Kim

Auto-generated profile, based on publicly available information

Jieun Kim

Department of Laboratory Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
CKCheol-In Kang
Cheol-In Kang
JKJieun Kim
Jieun Kim
DPDae Won Park
Dae Won Park
BKBaek-Nam Kim
Baek-Nam Kim
UHU-Syn Ha
U-Syn Ha
SWSeong-Heon Wie
Seong-Heon Wie
Kang CI, et al. Infect Chemother. 2018 Mar;50(1):67-100. https://doi.org/10.3947/ic.2018.50.1.67

1 February 2018 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
JRJohn Hoon Rim
John Hoon Rim
SKSe Hee Kim
Se Hee Kim
IHIn Sik Hwang
In Sik Hwang
SKSoon Sung Kwon
Soon Sung Kwon
JKJieun Kim
Jieun Kim
HKHoon-Chul Kang
Hoon-Chul Kang
We intended to evaluate diagnostic utility of a targeted gene sequencing by using next generation sequencing (NGS) panel in patients with intractable early-onset epilepsy (EOE) and find the efficient analytical step for increasing the diagnosis rate. We assessed 74 patients with EOE whose seizures started before 3 years of age using a customized NGS panel that included 172 genes. Single nucleotide variants (SNVs) and exonic and chromosomal copy number variations (CNVs) were intensively examined with our customized pipeline and crosschecked with commercial or pre-built software. Variants were filtered and prioritized by in-depth clinical review, and finally classified according to the American College of Medical Genetics and Genomics guidelines. Each case was further discussed in a monthly consensus meeting that included the participation of all laboratory personnel, bioinformaticians, geneticists, and clinicians. The NGS panel identified 28 patients (37.8%) with genetic abnormalities; 25 patients had pathogenic or likely pathogenic SNVs in 17 genes including SXTBP1 (n = 3), CDKL5 (n = 2), KCNQ2 (n = 2), SCN1A (n = 2), SYNGAP1 (n = 2), GNAO1 (n = 2), KCNT1 (n = 2), BRAT1, WWOX, ZEB2, CHD2, PRICKLE2, COL4A1, DNM1, SCN8A, MECP2, SLC9A6 (n = 1). The other 3 patients had pathogenic CNVs (2 duplications and 1 deletion) with varying sizes (from 2.5 Mb to 12 Mb). The overall diagnostic yield was 37.8% after following our step-by-step approach for clinical consensus. NGS is a useful diagnostic tool with great utility for patients with EOE. Diagnostic yields can be maximized with a standardized and team-based approach.

9 April 2020 in Horticulture, Environment, and Biotechnology
Verified
Journal Article
Closed access
PDF file
USUhram Song
Uhram Song
JKJieun Kim
Jieun Kim

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
MSMi-Ran Seo
Mi-Ran Seo
SKSeong-Jong Kim
Seong-Jong Kim
YKYeonjae Kim
Yeonjae Kim
JKJieun Kim
Jieun Kim
TCTae Yeal Choi
Tae Yeal Choi
HPHyunjoo Pai
Hyunjoo Pai
Seo MR, et al. J Korean Med Sci. 2014 Aug;29(8):1178-1181. https://doi.org/10.3346/jkms.2014.29.8.1178

21 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JKJieun Kim
Jieun Kim
YKYeonjae Kim
Yeonjae Kim
HPHyunjoo Pai
Hyunjoo Pai
The objective of this study was to identify the clinical characteristics of Clostridium difficile infections (CDIs) caused by toxin A-negative/toxin B-positive (A-B+) PCR ribotype 017 (R017) and A+B+ ribotype 018 (R018) strains, prevalent in Asian countries. From February 2010 through January 2013, all CDI patients in our hospital were enrolled; their medical records were retrospectively reviewed, and the isolates were characterized by toxigenic culture and PCR ribotyping. Based on the ribotypes, a total of 510 cases were categorized as R017 (139, 27.3%), R018 (157, 30.8%) and other ribotypes groups (214, 42.0%), and clinical variables were compared between R017 and other ribotypes, R018 and other ribotypes and R018 and R017 groups. The patients with R017 infections had a higher mean Charlson’s comorbidity index (OR 1.1, 1–1.21, p = 0.05), lower serum albumin (OR 0.47, 0.31–0.73, p = 0.001) and lower CRP levels (OR 0.96, 0.92–0.99, p = 0.022) than those with other ribotypes. R018 infections caused more azotemia (OR 4.06, 1.28–12.91, p = 0.018) and more frequent severe CDI (OR 1.87, 1.12–3.13, p = 0.016) than the other ribotypes infections. R017 and R018 infections were more often associated with toxin positive stools (OR 2.94, 1.65–4.09, p<0.001; OR 4.55, 2.82–7.33, p<0.001). In terms of treatment outcomes, R017 infections caused a marginally higher 30-day mortality than other ribotypes infection. In a final multiple logistic regression model, 30-day mortality was associated with leukocytosis (OR 2.45, 1.0–6.01, p = 0.05) and hypoalbuminemia (OR 4.57, 1.83–11.39, p = 0.001), but only marginally with R017 infection (OR 2.14, 0.88–5.22, p = 0.094). In conclusion, infections by C. difficile R018 strains tend to cause more severe disease, while there was a trend for higher mortality with R017 infections.

19 February 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
SJSOOK IN Jung
SOOK IN Jung
YKYe Eun Kim
Ye Eun Kim
NYNa Ra Yun
Na Ra Yun
CKChoon-Mee Kim
Choon-Mee Kim
DKDong-Min Kim
Dong-Min Kim
JSJun-Won Seo
Jun-Won Seo
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an acute, febrile, and potentially fatal tick-borne disease caused by the SFTS Phlebovirus. Here, we evaluated the effects of steroid therapy in Korean patients with SFTS. Methods: A retrospective study was performed in a multicenter SFTS clinical cohort from 13 Korean university hospitals between 2013 and 2017. We performed survival analysis using propensity score matching of 142 patients with SFTS diagnosed by genetic or antibody tests. Results: Overall fatality rate was 23.2%, with 39.7% among 58 patients who underwent steroid therapy. Complications were observed in 37/58 (63.8%) and 25/83 (30.1%) patients in the steroid and non-steroid groups, respectively (P < .001). Survival analysis after propensity score matching showed a significant difference in mean 30-day survival time between the non-steroid and steroid groups in patients with a mild condition [Acute Physiology and Chronic Health Evaluation II (APACHE II) score 5 days), and non-steroid groups, were 18.4, 22.4, and 27.3 days, respectively (P = .005). Conclusions: After steroid therapy, an increase in complications was observed among patients with SFTS. Steroid therapy should be used with caution, considering the possible negative effects of steroid therapy within 5 days of symptom onset or in patients with mild disease (APACHE II score <14).